Krsnaa Diagnostics

Pune, India Founded: 2011 • Age: 15 yrs Listed
Chain of radiology pathology laboratory centers
Request Access
Report Incorrect Data
Page last updated

About Krsnaa Diagnostics

Krsnaa Diagnostics is a publicly listed company based in Pune (India) founded in 2011 by Yogesh Arbat. Krsnaa Diagnostics has raised $23.61 million across 4 funding rounds from investors including Somerset Indus Capital Partners, Phi Capital and Kitara Capital. The company has 5,910 employees. Krsnaa Diagnostics was last valued at $61.18 million in March 2019. Its chief executive is Mitesh Dave. Its website krsnaadiagnostics.com draws about 265 thousand monthly visits. Its Indian entity Krsnaa Diagnostics Limited reported revenue of ₹743 Cr. Its focus areas include Clinical Laboratory Chains and Diversified. Its competitors include Thyrocare, Suraksha Diagnostics, Vijaya Diagnostic Centre, Aarthi Scans and Igenetic and 4 more; 6 of its 9 listed competitors have raised funding.

Company details

Chain of radiology pathology laboratory centers. Its diagnostic imaging includes MRI, CT, X-ray, ultrasound, remote radiology reporting, and consultation. It also offers home sample collection and telepathology.

  • Headquarters Pune, India
  • Employees 5,910
  • Founders Yogesh Arbat
  • Stage Public
  • Sectors
    Healthcare
  • Website category Finance · Banking Credit and Lending
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website krsnaadiagnostics.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Krsnaa Diagnostics Limited
Operational Areas
Healthcare → Diagnostics Laboratories
Key Metrics
  • Market Cap
    ₹1,663 Cr

    KRSNAA · NSE

  • Share Price
    ₹512.80

    -3.84% today

  • Revenue
    ₹773 Cr

    FY 2025-26 · +6.8% YoY

  • EBITDA
    ₹212 Cr

    Margin 27.4%

  • Net Profit
    ₹101 Cr

    FY 2025-26 · +36.8% YoY

  • P/E (TTM)
    17.8x

    P/B 1.8x

  • Total Equity Funding
    $23.61M (USD)

    in 4 rounds

  • Latest Funding Round
    $2.89M (USD), Series B

    Mar 2019

  • Investors
    Somerset Indus Capital Partners

    & 13 more

  • Employee Count
    5,910

Apps and channels of Krsnaa Diagnostics

Krsnaa Diagnostics publishes 1 mobile app with over 1M+ downloads.

Krsnaa Diagnostics
Google Play Health & Fitness Everyone Free 1M+ downloads
Developer: Medimaze
View on Google Play

Funding Insights of Krsnaa Diagnostics

Krsnaa Diagnostics has successfully raised a total of $23.61M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $2.89 million completed in March 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $23.61M
  • Total Rounds 4
  • Last Round Series B — $2.89M
  • First Round $1.47M

    (Mar 2014)

  • Investors Count 14

All 4 funding rounds of Krsnaa Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2019$2.89MSeries B$61.18MPhi Capital
–
Mar 2017$11.36MSeries B$45.99MPhi Capital
Kitara Capital, Somerset Indus Capital Partners
Jun 2015$7.9MSeries A$•••••Kitara Capital, Somerset Indus Capital Partners
Mayur Anand Sirdesai
Mar 2014$1.47MAngel Round$•••••Narayn Chighlikar, Rohit Dinanath Karpe
Rohit Dinanath Karpe, Manas Pukhraj Dhoka
Valuation history
DateValuationStage
Mar 2019$61.18M••••••••
Mar 2017$45.99M••••••••
Jun 2015$•••••••••••••
Mar 2014$•••••••••••••
Premium access

Full valuation and stage history of Krsnaa Diagnostics

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $61.18M (Mar 2019). 14 investors in total: 3 institutional and 11 angel.

Investors in Krsnaa Diagnostics

Krsnaa Diagnostics has secured backing from 14 investors, including venture fund and angel investors. Prominent investors backing the company include Somerset Indus Capital Partners, Phi Capital and Kitara Capital.

All
Venture Fund
Angel
InvestorDescriptionFounded YearDomainLocation
Phi Capital
Private equity fund focused on multiple sectors
–phicapital.inChennai, India
Kitara Capital
Investment management and co-investment services through global networks.
–kitaracapital.com-
Somerset Indus Capital Partners
Healthcare investments focused on accessibility, affordability, and ESG integration in India.
2011somersetinduscap.comMumbai, India

Kiran Kumar Bhise

-
–unknown_dedacbaaf9ae4948a-

Rajendra Mutha

-
–unknown_7158ed8957c043e59-

Sanjay Bhaskar Pandhare

-
–unknown_574b28d1c1ea4e189-

Mayur Anand Sirdesai

Co-founder of Swiggy, active angel investor in Indian startups
–unknown_c4c1df5fb75e43328-

Narayn Chighlikar

-
–unknown_79c711a28f4e45d48-

Rohit Dinanath Karpe

-
–unknown_4f16b911e1774f12a-

Sachin Pukhraj Dhoka

-
–unknown_8583b95c5a0b4e799-
Premium access

Investor details for Krsnaa Diagnostics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Krsnaa Diagnostics Limited (Krsnaa Diagnostics)

Krsnaa Diagnostics Limited is the primary company behind Krsnaa Diagnostics. The board of Krsnaa Diagnostics Limited currently have 7 directors; the longest-serving is Rajendra Khivraj Mutha, appointed in 2010. 24 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Rajendra Khivraj Mutha
DIN 01066737
Whole-time director22 Dec 201015 yrs 9 moKrsnaa Diagnostics Limited
Yash Prithviraj Mutha
DIN 07285523
Managing Director31 Jan 20197 yrs 8 moKrsnaa Diagnostics Limited
Prem Pradeep
DIN 07400417
Nominee Director08 Oct 20206 yrsKrsnaa Diagnostics Limited
Chetan Rameshchandra Desai
DIN 03595319
Director25 Apr 20215 yrs 5 moKrsnaa Diagnostics Limited
Adesh Kumar Gupta
DIN 00020403
Director28 May 20224 yrs 4 moKrsnaa Diagnostics Limited
Raju Venkatraman
DIN 00632071
Director25 Apr 20265 moKrsnaa Diagnostics Limited
Lilian Jessie Paul
DIN 02864506
Director25 Apr 20265 moKrsnaa Diagnostics Limited

People of Krsnaa Diagnostics

14 people are tracked at Krsnaa Diagnostics (10 in leadership, 4 in team); the tracked headcount is 5,910.

NameRoleGroup
Yogesh Arbat
Co-Founder & Managing DirectorLeadership
Pallavi Shantilal Bhatevara
Managing Director & Executive DirectorLeadership
Mitesh Dave
CEOLeadership
C.A. Pawan Daga
CFOLeadership
Pallavi Jain
Managing DirectorLeadership
Rupesh Dagar
Chief Business OfficerLeadership
Soumya Aparajita
Regional Head Human ResourcesLeadership
Manish Karekar
COO, PathologyLeadership
Pawan Daga
Chief Financial OfficerLeadership
Dr Shakti Aggarwal
Vice President (operations & Business Development)Leadership
Krutika Gugale
Senior ExecutiveTeam
Mousumi Bose
Senior TechnologistTeam
Tafseer Alam
Business Development And Project ManagerTeam
Vikas Mishra
Operations ManagerTeam
Premium access

Complete people profiles for Krsnaa Diagnostics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Krsnaa Diagnostics

Krsnaa Diagnostics is a publicly listed company on the NSE with ticker symbol KRSNAA in India, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Aug 2021
  • Listed onBSE: 543328 · NSE: KRSNAA
  • Listed entityKrsnaa Diagnostics Limited
  • Exchange sectorHealth services
  • ISININE08LI01020
  • Share price₹526.35 (-1.19% on the day) · 2026-10-14
  • Market capitalisation₹1,728 Cr
  • Price to earnings17.8
  • EPS (diluted, trailing year)₹29.65
  • Dividend yield0.38%
  • Volume (last session)59,960

Financials of Krsnaa Diagnostics

Exchange-reported figures of Krsnaa Diagnostics Limited, the listed company behind Krsnaa Diagnostics (NSE: KRSNAA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹773 Cr
+6.8% YoY
EBITDA
₹212 Cr
+11.4% YoY
Profit After Tax
₹101 Cr
+36.8% YoY
Net Worth
₹980 Cr
+11.1% YoY
Total Assets
₹1,585 Cr
+42.8% YoY
Total Debt
₹534 Cr
+162.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2016-17FY 2015-16
Income statement
Revenue77372462548745561.0239.14
Revenue growth+6.8%+15.8%+28.3%+7.0%-+55.9%-
EBITDA21219014412213118.618.87
EBITDA margin+27.4%+26.3%+23.1%+25.1%+28.9%+30.5%+22.7%
Profit before tax13010370.0080.2086.500.09(3.29)
Net profit10174.1356.8761.9768.58(0.09)(4.88)
Net profit margin+13.1%+10.2%+9.1%+12.7%+15.1%-0.2%-12.5%
EPS (₹)30.8824.0317.6019.7821.780.000.00
Balance sheet
Total assets1,5851,110992806755155160
Net worth98088381073968475.7260.92
Total debt53420416032.4840.9936.7880.97
Cash & bank36168.441751092427.2037.72
Net working capital529265258132221(11.67)30.35
Cash flow
Cash from operations14387.3324.3576.3012864.02(22.55)
Cash from investing(396)(99.61)(129)(109)(241)(53.98)(46.53)
Cash from financing27913.7584.19(33.15)176(40.57)105
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue236193181206193186175186
Revenue growth (YoY)+22.1%+3.5%+3.8%+10.6%+13.4%---
Other income7.2531.503.774.183.964.399.244.59
EBITDA57.9854.8746.3659.1551.4052.9945.0749.40
EBITDA margin+24.6%+28.5%+25.6%+28.7%+26.6%+28.5%+25.8%+26.5%
Depreciation27.9622.5922.6623.5921.6321.9622.7022.20
Interest14.8312.087.798.196.306.816.136.39
Profit before tax22.4451.7019.6831.5527.4328.6125.4825.40
Tax5.889.994.447.626.907.936.075.81
Net profit16.5641.7115.2423.9320.5320.6819.4119.59
EPS (₹)5.0412.704.667.256.256.285.885.92
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue691686594464455396258
Revenue growth+0.8%+15.4%+28.1%+2.0%+14.7%+53.4%-
EBITDA21319714612413593.81(114)
EBITDA margin+30.8%+28.7%+24.6%+26.8%+29.6%+23.7%-44.2%
Profit before tax13211071.9482.1989.59295(158)
Net profit10379.3358.6063.3770.89185(112)
Net profit margin+14.9%+11.6%+9.9%+13.7%+15.6%+46.7%-43.3%
EPS (₹)31.2625.6518.1420.2322.52284.73(216.83)
Balance sheet
Total assets1,5901,118997810758474558
Net worth992893815742687232(197)
Total debt53120216032.4840.99232231
Cash & bank35667.91175108242153127
Net working capital546276264137224128141
Cash flow
Cash from operations13489.3824.3975.4812911937.81
Cash from investing(391)(102)(129)(109)(241)(67.37)(76.65)
Cash from financing27813.9184.21(33.13)17620.035.78
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue211173159183176175165179
Revenue growth (YoY)+20.0%-0.9%-3.5%+2.3%+7.6%---
Other income7.2131.413.804.214.004.469.294.60
Total expenses154116112125126121117126
EBITDA56.7356.8347.6758.0050.1053.3047.9052.48
EBITDA margin+26.9%+32.8%+29.9%+31.7%+28.5%+30.5%+29.0%+29.4%
Depreciation27.7022.2522.5323.4721.5121.8022.6922.20
Interest14.7211.867.728.126.256.756.136.39
Profit before tax21.5254.1321.2230.6226.3429.2128.3728.49
Tax5.7010.754.737.406.788.156.776.53

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue236193181206193186175186
Revenue growth (YoY)+22.1%+3.5%+3.8%+10.6%+13.4%---
Other income7.2531.503.774.183.964.399.244.59
EBITDA57.9854.8746.3659.1551.4052.9945.0749.40
EBITDA margin+24.6%+28.5%+25.6%+28.7%+26.6%+28.5%+25.8%+26.5%
Depreciation27.9622.5922.6623.5921.6321.9622.7022.20
Interest14.8312.087.798.196.306.816.136.39
Profit before tax22.4451.7019.6831.5527.4328.6125.4825.40
Tax5.889.994.447.626.907.936.075.81
Net profit16.5641.7115.2423.9320.5320.6819.4119.59
EPS (₹)5.0412.704.667.256.256.285.885.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2016-17FY 2015-16
Revenue77372462548745561.0239.14
Revenue growth+6.8%+15.8%+28.3%+7.0%-+55.9%-
Other income43.3925.5416.8019.3814.912.343.23
Total expenses56153448136532442.4130.27
Employee cost0.0013711174.5654.1512.509.00
EBITDA21219014412213118.618.87
EBITDA margin+27.4%+26.3%+23.1%+25.1%+28.9%+30.5%+22.7%
Depreciation90.4688.3274.5553.7841.3911.586.44
Interest34.3624.6516.497.7018.499.288.95
Profit before tax13010370.0080.2086.500.09(3.29)
Tax28.9325.0813.1718.0918.120.181.61
Net profit10174.1356.8761.9768.58(0.09)(4.88)
Net profit margin+13.1%+10.2%+9.1%+12.7%+15.1%-0.2%-12.5%
EPS (₹)30.8824.0317.6019.7821.780.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2016-17FY 2015-16
Equity & liabilities
Share capital16.2216.1516.1515.7015.7070.1555.12
Reserves & surplus9648677947236695.575.80
Shareholders' funds (net worth)98088381073968475.7260.92
Minority interest0.000.000.000.000.000.000.00
Secured loans47926.9711.0016.5025.6332.3878.55
Unsecured loans55.1117714915.9815.364.402.42
Total debt53420416032.4840.9936.7880.97
Total liabilities1,5851,110992806755155160
Assets
Gross block1,04297187462749116091.54
Net block65667064747138613174.02
Capital work in progress2082.969.8525.4828.265.7820.05
Investments57.4331.540.290.290.290.570.53
Inventories26.6629.4835.8125.079.170.950.67
Sundry debtors29627817673.1057.8714.118.44
Cash & bank balances36168.441751092427.2037.72
Loans & advances55.4638.8233.9015.9525.223.369.38
Total current assets73841442122333425.6256.21
Total current liabilities20914916490.9911337.2925.86
Net working capital529265258132221(11.67)30.35
Total assets1,5851,110992806755155160
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2016-17FY 2015-16
Opening cash3.852.3822.7288.4524.6837.721.40
Net cash from operating activities14387.3324.3576.3012864.02(22.55)
Net cash from investing activities(396)(99.61)(129)(109)(241)(53.98)(46.53)
Net cash from financing activities27913.7584.19(33.15)176(40.57)105
Net change in cash26.381.47(20.35)(65.73)63.78(30.53)36.33
Closing cash36168.441751092427.2037.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2016-17FY 2015-16
Growth
Sales growth+6.8%+15.8%+28.3%+7.0%-+55.9%-
EBITDA growth+11.4%+31.8%+17.9%-7.0%-+109.8%-
PBT growth+27.0%+46.7%-12.7%-7.3%-+9998.0%+9997.0%
Net income growth+36.8%+30.4%-8.2%-9.6%-+98.2%-
Revenue CAGR (3Y)+16.6%+16.7%+117.2%+131.7%---
EBITDA CAGR (3Y)+20.1%+13.1%+97.9%+139.8%---
Profitability & leverage
Net income margin+13.1%+10.7%+9.1%+12.8%+15.0%-0.2%-12.5%
Return on capital employed-+12.1%+9.6%+11.3%+13.9%0.0%0.0%
Return on net worth-+9.2%+7.3%+8.7%+10.0%0.0%0.0%
Debt / equity-0.210.120.050.060.861.33
Long-term debt / equity-0.050.040.040.050.390.53
Interest cover28.3224.2123.6611.2420.53132.01368.31
Efficiency & per share
Fixed asset turnover-0.780.830.870.930.490.43
Inventory turnover-22.1720.5428.4549.6775.3358.42
Debtors turnover-3.195.017.447.875.414.64
EPS (₹)30.8824.0317.6019.7821.780.000.00
Dividend per share (₹)2.002.752.502.752.500.000.00
Book value per share (₹)0.00273.39250.79235.28217.9820.7921.24
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue211173159183176175165179
Revenue growth (YoY)+20.0%-0.9%-3.5%+2.3%+7.6%---
Other income7.2131.413.804.214.004.469.294.60
Total expenses154116112125126121117126
EBITDA56.7356.8347.6758.0050.1053.3047.9052.48
EBITDA margin+26.9%+32.8%+29.9%+31.7%+28.5%+30.5%+29.0%+29.4%
Depreciation27.7022.2522.5323.4721.5121.8022.6922.20
Interest14.7211.867.728.126.256.756.136.39
Profit before tax21.5254.1321.2230.6226.3429.2128.3728.49
Tax5.7010.754.737.406.788.156.776.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue691686594464455396258
Revenue growth+0.8%+15.4%+28.1%+2.0%+14.7%+53.4%-
Other income43.4125.6716.8019.4114.9326512.95
Total expenses478489448340320303373
Employee cost0.0011297.5765.6352.7429.9123.13
EBITDA21319714612413593.81(114)
EBITDA margin+30.8%+28.7%+24.6%+26.8%+29.6%+23.7%-44.2%
Depreciation89.7688.1674.5553.7841.3937.4432.41
Interest33.9424.5716.477.6818.4925.9424.66
Profit before tax13211071.9482.1989.59295(158)
Tax29.6526.7913.3818.6818.90111(46.38)
Net profit10379.3358.6063.3770.89185(112)
Net profit margin+14.9%+11.6%+9.9%+13.7%+15.6%+46.7%-43.3%
EPS (₹)31.2625.6518.1420.2322.52284.73(216.83)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.2216.1516.1515.7015.7024920.19
Reserves & surplus967871797724671(17.02)(217)
Shareholders' funds (net worth)992893815742687232(197)
Secured loans49116610716.5025.63213229
Unsecured loans40.6336.0853.0715.9815.3618.752.20
Total debt53120216032.4840.99232231
Total liabilities1,5901,118997810758474558
Assets
Gross block1,036968874627491377308
Net block651668647471386309275
Capital work in progress2082.969.8525.4828.263.729.13
Investments57.5031.620.360.360.360.290.29
Inventories25.6629.4835.8125.079.177.215.07
Sundry debtors30828317874.5559.3175.2961.43
Cash & bank balances35667.91175108242153127
Loans & advances54.6838.5633.8615.9225.5317.4719.85
Total current assets744419422224336253214
Total current liabilities19814315887.0511212572.26
Net working capital546276264137224128141
Total assets1,5901,118997810758474558
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.321.8622.1388.3224.68(46.65)(14.52)
Net cash from operating activities13489.3824.3975.4812911937.81
Net cash from investing activities(391)(102)(129)(109)(241)(67.37)(76.65)
Net cash from financing activities27813.9184.21(33.13)17620.035.78
Net change in cash21.731.46(20.27)(66.19)63.6571.32(33.06)
Closing cash25.0567.91175108242153127
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+0.8%+15.4%+28.1%+2.0%+14.7%+53.4%-
EBITDA growth+8.1%+34.6%+17.6%-7.7%+43.4%+182.2%-
PBT growth+20.7%+52.4%-12.5%-8.3%-69.7%+9998.0%-
Net income growth+29.4%+35.4%-7.5%-10.6%-61.7%+265.5%-
Revenue CAGR (3Y)+14.2%+14.7%+14.5%+21.6%+45.8%+91.0%+93.6%
EBITDA CAGR (3Y)+19.6%+13.5%+15.9%-+31.1%+86.3%-
Profitability & leverage
Net income margin+14.9%+12.1%+9.9%+13.7%+15.5%+46.6%-43.3%
Return on capital employed-+12.7%+9.8%+11.5%+17.0%+59.9%0.0%
Return on net worth-+9.7%+7.5%+8.9%+19.7%-204.0%0.0%
Debt / equity-0.210.120.050.3013.270.00
Long-term debt / equity-0.050.040.040.228.800.00
Interest cover27.6322.6523.0010.9019.8546.02-16.82
Efficiency & per share
Fixed asset turnover-0.740.790.831.051.160.87
Inventory turnover-21.0119.5327.1155.5464.5755.70
Debtors turnover-2.974.716.936.765.804.39
EPS (₹)31.2625.6518.1420.2322.52284.73(216.83)
Dividend per share (₹)2.002.752.502.752.500.000.00
Book value per share (₹)0.00274.65251.73235.63218.72(16.20)(410.62)

Timeline of Krsnaa Diagnostics

5 dated milestones of Krsnaa Diagnostics across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Krsnaa Diagnostics is founded.
  2. Funding First funding round of $1.5M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Series B, of $2.9M.
  5. IPO Lists on the stock exchange (IPO).

Competitors of Krsnaa Diagnostics

Krsnaa Diagnostics has 9 listed competitors in our database, 6 of them funded. They include Thyrocare, Suraksha Diagnostics, Vijaya Diagnostic Centre, Aarthi Scans and Igenetic, among others.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Thyrocare
thyrocare.com1996Mumbai, India$63.59M1,889
Diagnostic testing centers for pathology and health screenings are operated.
Suraksha Diagnostics
surakshanet.com2005Kolkata, India$49M1,180
Pathology, molecular diagnostics, and imaging services are provided.
Vijaya Diagnostic Centre
vijayadiagnostic.com1981Hyderabad, India––
Diagnostic services are offered via a chain of centers.
Aarthi Scans
aarthiscan.com2000Chennai, India–1,931
Chain of diagnostic centers
Igenetic
igenetic.com2013Mumbai, India$24.04M7
Provider molecular diagnostic solutions and services
Medall
medall.in2008Chennai, India$55.1M–
Medical diagnostic services are provided through a chain of centres.
GD
gd-lab.com2007Mumbai, India$11.5M291
A chain of clinical laboratories is operated for diagnostic services.
Health Ledger
healthledger.co.in2020Pune, India$380,041137
Chain of radiology & pathology laboratory centers
SONOSCAN
sonoscanhealthcare.com1990Kolkata, India–381
Offers blood tests, radiology, home collection, and online booking services.
Premium access

Detailed competitors of Krsnaa Diagnostics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Krsnaa Diagnostics

The website of Krsnaa Diagnostics (krsnaadiagnostics.com) receives about 265K visits a month and ranks #179,974 among all websites worldwide, #2,834 in Banking Credit and Lending.

  • Monthly visits
    265K

    ▲ 21.4% vs previous month

  • Unique visitors
    27.7K

    per month

  • Global rank
    #179,974

    among all websites

  • Category rank
    #2,834

    Finance · Banking Credit and Lending

Similar websites

Websites whose visitors overlap most with Krsnaa Diagnostics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
blallab.com
blallab.com
100%
–#502,396–
Agilus Diagnostics
agilusdiagnostics.com
67%
112.4K#270,512View details
Modern Diagnostics
mdrcindia.com
60%
19.5K#970,645View details
Suraksha Diagnostics
surakshanet.com
60%
101.3K#325,379View details
PRIMA Diagnostics
primadiagnostics.com
60%
25.9K#962,298View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 11 similar websites and full traffic analytics for Krsnaa Diagnostics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Diagnostics Laboratories

10 companies that operate in the same segment as Krsnaa Diagnostics (Diagnostics Laboratories), ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Thyrocare
Diagnostic testing centers for pathology and health screenings are operated.
1996Mumbai, Maharashtra, IndiaUSD 63.59 MUSD 88.36 M1,950
Dr Lal PathLabs
Chain of pathology and radiology labs
1949Gurugram, Haryana, IndiaUSD 13.9 MUSD 294.49 M5,310
Redcliffe Labs
Home-based diagnostic tests are booked via an online platform.
2018Noida, Uttar Pradesh, IndiaUSD 116.42 MUSD 41.86 M2,308
SRL Diagnostics
Pathology, radiology, wellness and clinical research services
1995Mumbai, Maharashtra, India–––
Metropolis India
Diagnostic centers are operated as a nationwide chain.
1981Mumbai, Maharashtra, IndiaUSD 228.2 MUSD 175.43 M5,180
RadNet
Radiology centers are operated as a nationwide chain.
1984Los Angeles, California, United States–USD 2.04 B8,550
MedGenome
DNA sequencing, bioinformatics, and multiomics services are provided.
2013Bengaluru, Karnataka, IndiaUSD 264.5 MUSD 29.55 M883
Akumin
Chain of radiology centers
2015Jacksonville, United States–USD 749.63 M5,486
Orange health
At-home diagnostic tests are booked and collected by phlebotomists.
2020Bengaluru, Karnataka, IndiaUSD 77.12 MUSD 3.34 M719
Core Diagnostics
Biomarker analysis and diagnostic tests are offered by the laboratory.
2012Gurugram, Haryana, IndiaUSD 17.26 MUSD 11.27 M496
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Krsnaa Diagnostics

Krsnaa Diagnostics to sell diagnostic equipment worth up to ₹120 crore - CNBC TV18
CNBCTV18 • 23 days ago
KRSNAA Diagnostics: Company Board Greenlights Sale of Diagnostic Equipment Worth Up to ₹120 Crore to Improve Asset Management.
Exchange Update • 23 days ago
Krsnaa Diagnostics shares surge 11% after securing 15-Year Punjab PET-CT Deal - The Economic Times
Economic Times • 1 month ago
Krsnaa Diagnostics share price jumps 11%: Stock in focus after company enters PET-CT segment | Stock Market News
mint • 1 month ago
Krsnaa Diagnostics signs 15-year pact for PET-CT facilities at 4 Punjab government hospitals - CNBC TV18
CNBCTV18 • 1 month ago
Krsnaa Diagnostics consolidated net profit declines 19.35% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
KRSNAA: Q1 FY27 revenue up 22% YoY; retail and PPP growth drive future margin and scale improvements
Quartr • 2 months ago
KRSNAA: Q1 FY27 revenue up 22% YoY, retail surges 64%, but margins compress on higher fixed costs
Quartr • 2 months ago
KRSNAA: Revenue and profit rose, dividend declared, and warrants issued to promoters amid tax appeals
Quartr • 2 months ago
Krsnaa Diagnostics Enters Agreement For CT Scan Facilities At 34 Institutions In Himachal Pradesh
Reuters • 3 months ago
Premium access

Complete news archive for Krsnaa Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Krsnaa Diagnostics

Krsnaa Diagnostics was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Krsnaa Diagnostics is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.

Mitesh Dave is the current CEO of Krsnaa Diagnostics.

Krsnaa Diagnostics is a funded company, having raised a total of $23.61M across 4 funding rounds to date. The company's 1st funding round was a Angel Round of $1.47M, raised on Mar 2014.

Krsnaa Diagnostics has 5,910 employees.

The primary company behind Krsnaa Diagnostics, Krsnaa Diagnostics Limited, reported revenue of ₹743 Cr for FY 2025, up 17% year on year.

Chain of radiology pathology laboratory centers. Its diagnostic imaging includes MRI, CT, X-ray, ultrasound, remote radiology reporting, and consultation. It also offers home sample collection and telepathology.

Krsnaa Diagnostics's top competitors include Thyrocare, Suraksha Diagnostics and Vijaya Diagnostic Centre.

Yes, Krsnaa Diagnostics is publicly traded on NSE under the ticker symbol KRSNAA.

Krsnaa Diagnostics has 14 investors. Key investors include Somerset Indus Capital Partners, Phi Capital, Kitara Capital, Kiran Kumar Bhise, and Rajendra Mutha.

The valuation of Krsnaa Diagnostics is $61.18M as of Mar 2019.

Krsnaa Diagnostics operates through Krsnaa Diagnostics Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available